Molecular Partners Ag (MOLN) Interest Coverage Ratio (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Interest Coverage Ratio of 1195.91 for Q1 2026, up 7461.27% year-on-year from 15.82 in Q1 2025, and up 10098.95% on a QoQ basis from 11.96 in Q4 2025.
Molecular Partners Ag (MOLN) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Interest Coverage Ratio for 7 consecutive years, with 1195.91 the latest figure, recorded in Q1 2026.
- Quarterly Interest Coverage Ratio rose 7461.27% year-over-year to 1195.91 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.15 (up 99.32% YoY) and the FY2025 annual result came in at 11.52, up 99.29% from the prior year.
- Interest Coverage Ratio climbed to 1195.91 in Q1 2026 per MOLN's latest filing, from 11.96 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for MOLN reached as high as 1195.91 in Q1 2026 and fell as low as 1432.37 in Q4 2024.
- A 5-year average of 85.88 and a median of 15.82 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio plunged 12464.67% — and 2026, when it surged 7461.27%.
- Year by year, Interest Coverage Ratio stood at 199.59 in 2022, then sank by 105.71% to 11.4 in 2023, then slumped by 12464.67% to 1432.37 in 2024, then jumped by 99.16% to 11.96 in 2025, then soared by 10098.95% to 1195.91 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1195.91, 11.96, and 76.39 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 1,195.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,195.91 |
| Dec 31, 2025 | -11.96 |
| Sep 30, 2025 | 76.39 |
| Jun 30, 2025 | -4.95 |
| Mar 31, 2025 | 15.82 |
| Dec 31, 2024 | -1,432.37 |
| Sep 30, 2024 | 7.48 |
| Jun 30, 2024 | -887.56 |
| Mar 31, 2024 | 1,133.50 |
| Dec 31, 2023 | -11.40 |
| Sep 30, 2023 | 1,040.91 |
| Jun 30, 2023 | 13.32 |
| Mar 31, 2023 | 27.53 |
| Dec 31, 2022 | 199.59 |
| Sep 30, 2022 | 114.86 |
| Jun 30, 2022 | -633.00 |
| Mar 31, 2022 | 615.97 |
| Dec 31, 2021 | -113.54 |
| Sep 30, 2021 | 94.96 |
| Jun 30, 2021 | 106.12 |